KGA-2727
Product Specifications
UNSPSC Description
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy[1].
Target Antigen
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/kga-2727.html
Purity
98.84
Solubility
DMSO : 200 mg/mL (ultrasonic)|Ethanol : 100 mg/mL (ultrasonic)|H2O : 20 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C(N)CCNCCCOC1=CC=C(CC2=C(C(C)C)NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C(C)=C1
Molecular Weight
536.62
References & Citations
[1]Shibazaki T, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012 Aug;342(2):288-96.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-123797/KGA-2727-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-123797/KGA-2727-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
666842-36-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
